tiprankstipranks
Advertisement
Advertisement

HK:9966 Stock Latest News

Alphamab Oncology Launches HK$80 Million On-Market Share Buyback Plan
Company AnnouncementsAlphamab Oncology Launches HK$80 Million On-Market Share Buyback Plan
11d ago
9966
Alphamab Oncology Swings to Loss as R&D Surge Drives Aggressive Cancer Pipeline Expansion
PremiumCompany Announcements
Alphamab Oncology Swings to Loss as R&D Surge Drives Aggressive Cancer Pipeline Expansion
12d ago
9966
Alphamab Oncology’s HER2 Drug Anbenitamab Wins Priority NMPA Review for First-Line Breast Cancer
PremiumCompany Announcements
Alphamab Oncology’s HER2 Drug Anbenitamab Wins Priority NMPA Review for First-Line Breast Cancer
21d ago
9966
Alphamab Oncology Sets Board Meeting to Approve 2026 Interim Results
PremiumCompany Announcements
Alphamab Oncology Sets Board Meeting to Approve 2026 Interim Results
27d ago
9966
Alphamab’s Anbenitamab Breast Cancer NDA Gains Priority Review in China
PremiumCompany Announcements
Alphamab’s Anbenitamab Breast Cancer NDA Gains Priority Review in China
1M ago
9966
Alphamab licenses key cancer drug JSKN016 to Pathos AI in US$2.1 billion-plus deal
PremiumCompany AnnouncementsAlphamab licenses key cancer drug JSKN016 to Pathos AI in US$2.1 billion-plus deal
1M ago
9966
Alphamab Wins China Phase III Nod for Novel Cervical Cancer Therapy
Premium
Company Announcements
Alphamab Wins China Phase III Nod for Novel Cervical Cancer Therapy
1M ago
9966
Alphamab’s Anbenitamab Wins Breakthrough Status Again in HER2+ Breast Cancer
Premium
Company Announcements
Alphamab’s Anbenitamab Wins Breakthrough Status Again in HER2+ Breast Cancer
2M ago
9966
Alphamab Oncology Gains Strong Shareholder Backing for Capital Mandates and Board Re-elections
PremiumCompany Announcements
Alphamab Oncology Gains Strong Shareholder Backing for Capital Mandates and Board Re-elections
3M ago
9966
Alphamab’s Anbenitamab Scores Phase III Win in HER2+ Breast Cancer
PremiumCompany Announcements
Alphamab’s Anbenitamab Scores Phase III Win in HER2+ Breast Cancer
3M ago
9966
Alphamab Executives Lift Stakes as HER2 Oncology Pipeline Advances
PremiumCompany Announcements
Alphamab Executives Lift Stakes as HER2 Oncology Pipeline Advances
3M ago
9966
Alphamab Oncology Reports Promising Phase I Data for Bispecific ADC JSKN016 in HER2-Negative Breast Cancer
PremiumCompany Announcements
Alphamab Oncology Reports Promising Phase I Data for Bispecific ADC JSKN016 in HER2-Negative Breast Cancer
3M ago
9966
Alphamab’s Anbenitamab Delivers Superior Phase III Results in HER2-Positive Breast Cancer
PremiumCompany AnnouncementsAlphamab’s Anbenitamab Delivers Superior Phase III Results in HER2-Positive Breast Cancer
3M ago
9966
Alphamab Wins China Approval for First HER2 Bispecific Antibody in Gastric Cancer
Premium
Company Announcements
Alphamab Wins China Approval for First HER2 Bispecific Antibody in Gastric Cancer
3M ago
9966
Alphamab Oncology Sets AGM to Seek Share Buyback and Issuance Mandates
Premium
Company Announcements
Alphamab Oncology Sets AGM to Seek Share Buyback and Issuance Mandates
4M ago
9966
Alphamab Doses First Patient in Phase II Trial of JSKN033 for Advanced Cervical Cancer
PremiumCompany Announcements
Alphamab Doses First Patient in Phase II Trial of JSKN033 for Advanced Cervical Cancer
4M ago
9966
Alphamab Oncology Grants 250,000 Restricted Award Shares to Key Employees
PremiumCompany Announcements
Alphamab Oncology Grants 250,000 Restricted Award Shares to Key Employees
5M ago
9966
Alphamab Oncology Secures Waiver to Appoint Joint Company Secretary
PremiumCompany Announcements
Alphamab Oncology Secures Waiver to Appoint Joint Company Secretary
5M ago
9966
Alphamab’s KN026 Breast Cancer Trial Secures High-Profile ASCO 2026 Slot
PremiumCompany Announcements
Alphamab’s KN026 Breast Cancer Trial Secures High-Profile ASCO 2026 Slot
5M ago
9966
Alphamab Oncology Reshapes Company Secretariat, Seeks Listing Rules Waiver
PremiumCompany AnnouncementsAlphamab Oncology Reshapes Company Secretariat, Seeks Listing Rules Waiver
5M ago
9966
Alphamab’s KN026 Phase III Breast Cancer Trial Hits Key Efficacy Goal
Premium
Company Announcements
Alphamab’s KN026 Phase III Breast Cancer Trial Hits Key Efficacy Goal
5M ago
9966
Alphamab Oncology Swings to Loss as R&D Spend Climbs but Cancer Pipeline Advances
Premium
Company Announcements
Alphamab Oncology Swings to Loss as R&D Spend Climbs but Cancer Pipeline Advances
6M ago
9966

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >